HPV cancer vaccine finishes successful trial
The trial was conducted in an open lab and involved 26 patients who were required to have HPV-positive vulvar, cervical, vaginal, head, neck, penile or anal cancers at an advanced stage.
The vaccine, VicOryx, treats p16INK4a-overexpressing HPV-positive cancer patients. Before or after their standard therapies, the subjects received a diffuse expression of p16INK4a inside the tumor. The results showed that the vaccine is safe and provoked the body’s immune system into a response against the illness.
There are currently two prophylactic vaccines that stimulate HPV-type immunity, but these vaccines do not have the same therapeutic outcomes for HPV infections.
"We are pleased to announce another successful completion of another clinical trial,” Dr. Bernard Huber, CEO and Founder of ORYX, said. “The VicOryx trial has shown the important potential of our therapeutic p16 vaccine. Inspired by the ground-breaking HPV research of Nobel Laureate Professor (Harald) zur Hausen, member of the ORYX Scientific Advisory Board, and based on the VicOryx data, we are convinced that this vaccination approach can be an effective therapeutic strategy for patients with HPV-associated cancers."
The company will present its results at the BIO-European Conference in Paris this month.